Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)

As 'low­er than pro­ject­ed' da­ta send it back to the draw­ing board, Sanofi takes $1.6B hit on IL-2

One of the key pro­grams that in­spired Sanofi’s $2.5 bil­lion buy­out of Syn­thorx in late 2019 is now the sub­ject of a $1.6 bil­lion write­down.

Sanofi dis­closed in its Q3 earn­ings that it’s clos­ing down Phase II plat­form tri­als for SAR444245, an IL-2 can­di­date that it had hoped would serve as a next-gen foun­da­tion of the on­col­o­gy fran­chise. An ear­ly look at the da­ta, it said, sug­gests ef­fi­ca­cy that’s “low­er than pro­ject­ed.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.